Results of Annual General Meeting

Blog image

Alderley Park, 31 March 2022 – BiVictriX Therapeutics plc (AIM: BVX), an emerging biotechnology company applying a novel approach to develop next generation cancer therapies using insights derived from frontline clinical experience, today announces that at its Annual General Meeting, held today at 12.00pm, all resolutions were duly passed. 


Contact BivictriX

Please submit the form below and we shall be in touch
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
AntibodyPatient Image